Chemotherapy for advanced hormone refractory prostate cancer

Urology

Volumn 54, Issue 6 SUPPL. 1, 1999, Pages 30-35

  Petrylak, Daniel P ^a  

^a Genitourinary Oncology Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; HYDROCORTISONE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RETINOID; SURAMIN; VINBLASTINE;

BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; EDEMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

EID: 0032761807     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00452-5     Document Type: Article

References (32)

1. Landis SH, Murray T, Boldin S, and Wingo PA. Cancer statistics, 1999. CA 49: 8-32, 1999.
2. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer. 71:1993;1098-1109.
3. McDonnel T.J., Navone N.M., Troncoso P., et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 157:1997;569-574.
4. Raffo A.J., Perlman H., Chen M.W., Day M.L., Streitman J.S., Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55:1995;4438-4445.
5. Tu S.M., McConnel K., Marin M.C., Campbell M.L., Fernandez A., von Eschenbach AC, McDonnell T.J. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett. 13:1995;147-155.
6. Uslu R., Borsellino N., Frost T., et al. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. Clin Cancer Res. 3:1997;963-972.
7. Meyers F.J., Gumerlock P.H., Chi S.G., Borchers H., Deitch A.D., deVere White R.W. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer. 15:1998;2534-2539.
8. Kelly W.K., Scher H.I., Mazumadar M., et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 11:1993;607-615.
9. Smith D.C., Dunn R.L., Strawderman M.S., Pienta K.J. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 16:1998;1835-1843.
10. Thalmann G.N., Sikes R.A., Chang S., et al. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Institute. 88:1996;794-802.
11. Moore M.J., Osoba D., Murphy K., Tannock I.F., Armitage A., Findlay B., Coppin C., Neville A., Venner P., Wilson J. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 12:1994;689-694.
12. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian randomized trial symptomatic hormone-resistant prostate cancer: a Canadian randomized trial palliative end points . J Clin Oncol. 14:1996;1756-1764.
13. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer results of the Cancer and Leukemia Group B 9182 Study . J Clin Oncol. 17:1999;2506-2513.
14. Perry C.A., McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs and Aging. 7:1995;149-174.
15. Seidman A.D., Scher H.I., Petrylak D., Dershaw D.D., Curley T. Estramustine and vinblastine use of prostate specific antigen as a clinical trial end point in hormone refractory prostate cancer . J Urol. 147:1992;931-934.
16. Amato RJ, Ellenhorst J, Bui C, and Logothetis CJ: Estramustine and vinblastine for patients with androgen-independent adenocarcinoma of the prostate. Urol Oncol 2: 168-172, 1995.
17. Hudes G.H., Greenberg R., Krigel R., et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone refractory prostate cancer. J Clin Oncol. 10:1992;154-1761.
18. Pienta K.J., Redman B., Hussain M., et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 12:1994;2005-2012.
19. Hudes G., Einhorn L., Ross E., et al. Vinblastine vs. vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer a Hoosier Oncology Group and Fox Chase Network Phase III trial . J Clin Oncol. 17:1999;3160-3166.
20. Lavelle F., Bissery M.C., Combeau C., Riou J.F., Vrignaud P., Andre S. Preclinical evaluation of docetaxel (taxotere). Semin Oncol. 22:(2 Suppl 4):1995;3-16.
21. Haldar S, Basu A, and Croce C: Bcl-2 is the guardian of microtubule integrity. Canc Res 57: 229-233, 1997.
22. Roth B.J., Yeap B.Y., Wilding G., et al. Taxol in advanced hormone-refractory prostate carcinoma phase II trial of the eastern cooperative oncology group. Cancer. 72:1993;2457-2460.
23. Schultz M., Wei J., Picus J., Cochran J. A phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC) (abst). Proc Am Soc Clin Oncol. 18:1999;355a.
24. Kreis W., Budman D.R., Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol. 79:1997;196-202.
25. Hudes G.R., Nathan F., Khater C., et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 15:1997;3156-3163.
26. Petrylak D.P., Macarthur R.B., O'Connor J., Shelton G., Judge T., Balog J., Pfaff C., Bagiella E., Heitjan D., Fine R., et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 17:1999;958-967.
27. Kreis W., Budman D.R., Fetten J., Gonzales A.L., Barile B., Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 10:1999;33-38.
28. Sheton G, Gerson H, Zuech N, et al.: Activity of docetaxel (D) + estramustine (E) after dexamethasone (Dex) treatment in patients (pts) with androgen-insensitive prostate cancer (abst). Proc Am Soc Clin Oncol 17: 343a, 22, 1998.
29. Savarese D.M., Taplin M.E., Marchesani B., et al. A phase II study of docetaxel, estramustine, and low dose hydrocortisone in hormone refractory prostate cancer CALGB 9780 (abst) . Proc Am Soc Clin Oncol. 18:1999;321a.
30. Sinibaldi V.J., Carducci M.A., Moore-Cooper S. A phase II study evaluating a one day course of estramustine phosphate (EMP) and docetaxel (D) in patients (pts) with hormone refractory prostate cancer (HRPC) (abst). Proc Am Soc Clin Oncol. 18:1999;322a.
31. Haas N., Garay C., Roth B., et al. Weekly paclitaxel by 3 hour infusion plus oral estramustine (EMP) in metastatic hormone-refractory prostate cancer (HRPC) (abst). Proc Am Soc Clin Oncol. 18:1999;340a.
32. Natale R.B., Zaretsky S. Phase I/II study of estramustine (E) and taxotere(T) in patients with metastatic hormone-refractory prostate cancer (HRPC) (abst). Proc Am Soc Clin Oncol. 17:1998;348a.